Outcomes in men with metastatic castration-resistant prostate cancer and tumors with certain androgen receptor (AR) mutations

Tyler F. Stewart, et al.

September 9, 2022
European Society for Medical Oncology (ESMO)


You are now leaving arvinas.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

Skip to content ;